secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amphastar Pharmaceuticals, Inc. (AMPH)
CIK:        0001297184
Form:       8-K
Filed at:   2022-08-08T23:59:59+00:00
Accession:  0001297184-22-000041
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amphastar Q2 2022 net revenue up 21.5% YoY to $123.5M; GAAP EPS $0.33
---------------------------------------------------------------------

- Net revenues $123.5M for Q2 2022, up from $101.7M in Q2 2021 (21.5% increase).
- GAAP net income $17.3M ($0.33 diluted EPS) vs $7.8M ($0.16) in Q2 2021.
- Adjusted non-GAAP net income $20.7M ($0.39 diluted EPS) vs $10.6M ($0.21) in Q2 2021.
- CEO cites strong sales momentum; expects continued growth from ganirelix and vasopressin launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1297184/000129718422000041/0001297184-22-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1297184/000129718422000041/amph-20220808x8k.htm
  HTML page:      https://secwatch.observer/filing/0001297184-22-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer